Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) announced inducement grants on April 1, 2026 for nine newly hired employees: 42,650 stock options and 9,050 RSUs under the 2023 Inducement Plan.
The options carry a $17.39 exercise price (closing price on grant date), a 10-year term, and a four-year vesting schedule (25% after 12 months, then monthly). RSUs vest over four years with 25% after 12 months and quarterly thereafter, all subject to continued employment and award agreements.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – VOR
On the day this news was published, VOR gained 3.80%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.6% during that session. Argus tracked a trough of -2.8% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $35M to the company's valuation, bringing the market cap to $942.76M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VOR gained 21.36% with elevated volume, while key biotech peers like PRQR and ALLO showed modest single-digit gains and TLSA declined, pointing to a stock-specific move rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Earnings and update | Positive | +1.5% | Q4 and 2025 results plus funding runway and Phase 3 development update. |
| Mar 30 | Clinical trial progress | Positive | +1.5% | First patient dosed in global Phase 3 UPSTREAM SjD telitacicept trial. |
| Mar 27 | Private placement | Neutral | +1.9% | $75 million private placement at $14.05 per share with TCGX-led group. |
| Mar 23 | Inducement grants | Neutral | -4.3% | Stock options and RSUs granted under 2023 Inducement Plan to new hires. |
| Feb 23 | Conference participation | Neutral | +13.8% | Participation and presentation at the 46th Annual TD Cowen Health Care Conference. |
Recent VOR news, including Phase 3 trial progress, financing, and corporate events, has generally seen positive single-digit to low-teens price moves, with no consistent pattern of selling on good news.
Over recent months, Vor Bio has reported multiple catalysts, including a Phase 3 UPSTREAM SjD trial first patient dosed on Mar 30, 2026 and a $75 million private placement announced on Mar 27, 2026. Earnings on Mar 30, 2026 highlighted substantial cash and investment levels and projected funding into early 2029. Earlier, inducement grants and conference participation were disclosed. Compared with today’s inducement grants, prior news involved more fundamental clinical and financing milestones, each met with generally positive price reactions.
Regulatory & Risk Context
An effective Form S-3 filed on Jan 29, 2026 registers 13,876,032 existing shares for resale from a prior private placement at $10.81 per share. Vor Bio does not receive proceeds from these resales, but selling stockholder activity could add secondary supply to the market.
Market Pulse Summary
This announcement details stock options on 42,650 shares and 9,050 RSUs granted to 9 new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4). These awards, with a $17.39 exercise price and four-year vesting, follow a period of substantial clinical and financing activity, including a $75 million private placement and Phase 3 trial progress. Investors may track how equity compensation, registered resale shares, and future clinical milestones interact with the existing capital structure.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock units financial
stock options financial
AI-generated analysis. Not financial advice.
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 42,650 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 9,050 shares of Vor Bio’s common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
The stock options have a ten-year term, and an exercise price of
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com
Media & Investor Contacts: Carl Mauch cmauch@vorbio.com